Erratum: Zhang Y, Moschetta M, Huynh D, et al. Pyk2 promotes tumor progression in multiple myeloma. Blood. 2014;124(17):2675-2686. (Blood (2014) 124(17) (2675–2686), (S0006497120354380), (10.1182/blood-2014-03-563981));Pyk2 promotes tumor progression in multiple myeloma

Blood

Volumn 124, Issue 17, 2014, Pages 2675-2686

  Zhang, Yu ^a,b   Moschetta, Michele ^a   Huynh, Daisy ^a   Tai, Yu Tzu ^a   Zhang, Yong ^a   Zhang, Wenjing ^a,c   Mishima, Yuji ^a   Ring, Jennifer E ^d   Tam, Winnie F ^d   Xu, Qunli ^d   Maiso, Patricia ^a   Reagan, Michaela ^a   Sahin, Ilyas ^a   Sacco, Antonio ^a   Manier, Salomon ^a   Aljawai, Yosra ^a   Glavey, Siobhan ^a   Munshi, Nikhil C ^a   Anderson, Kenneth C ^a   Pachter, Jonathan ^d   Roccaro, Aldo M ^a,e   Ghobrial, Irene M ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b First People's Hospital of Yunnan Province   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d Verastem Oncology Chief Medical Officer   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; DEXAMETHASONE; FOCAL ADHESION KINASE 2; FOCAL ADHESION KINASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; MYC PROTEIN; PAXILLIN; PROTEIN; PROTEIN P21; SHORT HAIRPIN RNA; SRC PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; SYNDECAN 1; UNCLASSIFIED DRUG; VC 4718; WNT PROTEIN; AMINOPYRIDINE DERIVATIVE; GREEN FLUORESCENT PROTEIN; PND 1186; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME 8P; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GAIN OF FUNCTION MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; MESENCHYMAL STROMA CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL CYCLE; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; LUMINESCENCE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SCID MOUSE; SURVIVAL; TUMOR CELL LINE; TUMOR VOLUME; WNT SIGNALING PATHWAY;

AMINOPYRIDINES; ANIMALS; BETA CATENIN; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DISEASE PROGRESSION; FEMALE; FOCAL ADHESION KINASE 2; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; LUMINESCENT MEASUREMENTS; MICE, SCID; MULTIPLE MYELOMA; PROTEIN KINASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SURVIVAL ANALYSIS; TUMOR BURDEN; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908224321     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood.2024025297     Document Type: Erratum

References (47)

1. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2(3):175-187.
2. Agarwal A, Ghobrial IM. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res. 2013;19(5):985-994.
3. Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009;28(1-2):35-49.
4. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005;6(1):56-68.
5. Schaller MD. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci. 2010;123(Pt 7):1007-1013.
6. Zhao J, Zheng C, Guan J. Pyk2 and FAK differentially regulate progression of the cell cycle. J Cell Sci. 2000;113(Pt 17):3063-3072.
7. Yin B. Focal adhesion kinase as a target in the treatment of hematological malignancies. Leuk Res. 2011;35(10):1416-1418.
8. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature. 1996;383(6600):547-550.
9. Sieg DJ, Ilić D, Jones KC, Damsky CH, Hunter T, Schlaepfer DD. Pyk2 and Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated signaling events but Pyk2 does not fully function to enhance FAK- cell migration. EMBO J. 1998;17(20):5933-5947.
10. Salgia R, Avraham S, Pisick E, et al. The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J Biol Chem. 1996;271(49):31222-31226.
11. Astier A, Avraham H, Manie SN, et al. The related adhesion focal tyrosine kinase is tyrosine-phosphorylated after beta1-integrin stimulation in B cells and binds to p130cas. J Biol Chem. 1997;272(1):228-232.
12. Weis SM, Lim ST, Lutu-Fuga KM, et al. Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J Cell Biol. 2008;181(1):43-50.
13. Fan H, Guan JL. Compensatory function of Pyk2 protein in the promotion of focal adhesion kinase (FAK)-null mammary cancer stem cell tumorigenicity and metastatic activity. J Biol Chem. 2011;286(21):18573-18582.
14. Guinamard R, Okigaki M, Schlessinger J, Ravetch JV. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat Immunol. 2000;1(1):31-36.
15. Ilić D, Furuta Y, Kanazawa S, et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature. 1995;377(6549):539-544.
16. Buckbinder L, Crawford DT, Qi H, et al. Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis. Proc Natl Acad Sci USA. 2007;104(25):10619-10624.
17. Kuang BH, Zhang MQ, Xu LH, et al. Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for nonsmall-cell lung cancer progression and patients' overall survival. Br J Cancer. 2013;109(5):1252-1263.
18. Wendt MK, Schiemann BJ, Parvani JG, Lee YH, Kang Y, Schiemann WP. TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer. Oncogene. 2013;32(16):2005-2015.
19. Leleu X, Jia X, Runnels J, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007;110(13):4417-4426.
20. Zhan F, Barlogie B, Arzoumanian V, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109(4):1692-1700.
21. Hanamura I, Huang Y, Zhan F, Barlogie B, Shaughnessy J. Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leukemia. 2006;20(7):1288-1290.
22. Liu Y, Quang P, Braggio E, et al. Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma. PLoS ONE. 2013;8(6):e66982.
23. Roccaro AM, Sacco A, Thompson B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009;113(26):6669-6680.
24. Tanjoni I, Walsh C, Uryu S, et al. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol Ther. 2010;9(10):764-777.
25. Walsh C, Tanjoni I, Uryu S, et al. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther. 2010;9(10):778-790.
26. Shapiro IM, Kolev VN, Vidal CM, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6(237):237ra68.
27. Sutlu T, Alici E, Jansson M, et al. The prognostic significance of 8p21 deletion in multiple myeloma. Br J Haematol. 2009;144(2):266-268.
28. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-607.
29. Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006;42(11):1564-1573.
30. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585-598.
31. Chauhan D, Hideshima T, Pandey P, et al. RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene. 1999;18(48):6733-6740.
32. Chauhan D, Pandey P, Hideshima T, et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem. 2000;275(36):27845-27850.
33. Lev S, Moreno H, Martinez R, et al. Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions. Nature. 1995;376(6543):737-745.
34. Okenwa C, Kumar A, Rego D, et al. SHP-1-Pyk2-Src protein complex and p38 MAPK pathways independently regulate IL-10 production in lipopolysaccharide-stimulated macrophages. J Immunol. 2013;191(5):2589-2603.
35. Sorokin A, Kozlowski P, Graves L, Philip A. Protein-tyrosine kinase Pyk2 mediates endothelin-induced p38 MAPK activation in glomerular mesangial cells. J Biol Chem. 2001;276(24):21521-21528.
36. Tokiwa G, Dikic I, Lev S, Schlessinger J. Activation of Pyk2 by stress signals and coupling with JNK signaling pathway. Science. 1996;273(5276):792-794.
37. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387-398.
38. Derksen PW, Tjin E, Meijer HP, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA. 2004;101(16):6122-6127.
39. Qiang YW, Walsh K, Yao L, et al. Wnts induce migration and invasion of myeloma plasma cells. Blood. 2005;106(5):1786-1793.
40. Sukhdeo K, Mani M, Zhang Y, et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA. 2007;104(18):7516-7521.
41. Otero K, Turnbull IR, Poliani PL, et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat Immunol. 2009;10(7):734-743.
42. Despeaux M, Chicanne G, Rouer E, et al. Focal adhesion kinase splice variants maintain primitive acute myeloid leukemia cells through altered Wnt signaling. Stem Cells. 2012;30(8):1597-1610.
43. Holien T, Va˚tsveen TK, Hella H, Waage A, Sundan A. Addiction to c-MYC in multiple myeloma. Blood. 2012;120(12):2450-2453.
44. Chng WJ, Huang GF, Chung TH, et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 2011;25(6):1026-1035.
45. Stokes JB, Adair SJ, Slack-Davis JK, et al. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011;10(11):2135-2145.
46. Roberts WG, Ung E, Whalen P, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res. 2008;68(6):1935-1944.
47. Bagi CM, Christensen J, Cohen DP, et al. Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. Cancer Biol Ther. 2009;8(9):856-865.